145 related articles for article (PubMed ID: 36450996)
1. Correlation of Non-tumoral Liver Dose with Treatment-Related Adverse Events in Patients with Hepatocellular Carcinoma Treated with Glass-Based Yttrium-90 Radioembolization.
Webster LA; Villalobos A; Cheng B; Xing M; Majdalany BS; Bercu ZL; Cristescu MM; Brandon D; Schuster D; Baum Y; Loya MF; Kokabi N
Cardiovasc Intervent Radiol; 2023 Jan; 46(1):60-68. PubMed ID: 36450996
[TBL] [Abstract][Full Text] [Related]
2. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres.
Villalobos A; Arndt L; Cheng B; Dabbous H; Loya M; Majdalany B; Bercu Z; Kokabi N
J Vasc Interv Radiol; 2023 Jul; 34(7):1226-1234. PubMed ID: 36958669
[TBL] [Abstract][Full Text] [Related]
4. Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with
Watanabe M; Grafe H; Theysohn J; Schaarschmidt B; Ludwig J; Jochheim L; Jeschke M; Schmidt H; Fendler WP; Moraitis A; Herrmann K; Pomykala KL; Weber M
J Nucl Med; 2023 Jul; 64(7):1102-1108. PubMed ID: 37290792
[TBL] [Abstract][Full Text] [Related]
5. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
6. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
7. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
8. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
[TBL] [Abstract][Full Text] [Related]
9. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
10. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
[TBL] [Abstract][Full Text] [Related]
11. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
13. Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study.
Sankhla T; Cheng B; Nezami N; Xing M; Sethi I; Bercu Z; Brandon D; Majdalany B; Schuster DM; Kokabi N
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638392
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
15. 3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization.
Grisanti F; Prieto E; Bastidas JF; Sancho L; Rodrigo P; Beorlegui C; Iñarrairaegui M; Bilbao JI; Sangro B; Rodríguez-Fraile M
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3048-3057. PubMed ID: 33674893
[TBL] [Abstract][Full Text] [Related]
16. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis.
Cheng B; Sethi I; Villalobos A; Wagstaff W; Schuster DM; Bercu Z; Brandon D; Kokabi N
Nucl Med Commun; 2021 Aug; 42(8):892-898. PubMed ID: 33795611
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
Gordon AC; Gupta AN; Gabr A; Thornburg BG; Kulik LM; Ganger DR; Maddur H; Flamm SL; Boike JR; Moore CM; Borja-Cacho D; Christopher DA; Katariya NN; Ladner DP; Caicedo-Ramirez JC; Riaz A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2021 Feb; 32(2):211-219. PubMed ID: 33349507
[TBL] [Abstract][Full Text] [Related]
18. Radioembolization of hepatocarcinoma with
Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
[TBL] [Abstract][Full Text] [Related]
19. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
Vouche M; Lewandowski RJ; Atassi R; Memon K; Gates VL; Ryu RK; Gaba RC; Mulcahy MF; Baker T; Sato K; Hickey R; Ganger D; Riaz A; Fryer J; Caicedo JC; Abecassis M; Kulik L; Salem R
J Hepatol; 2013 Nov; 59(5):1029-36. PubMed ID: 23811303
[TBL] [Abstract][Full Text] [Related]
20. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
